Summary of COVID-19 leritrelvir studies

1. Wang et al., Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial

40 patient leritrelvir early treatment RCT: 35% faster recovery (p=0.04) and 21% improved viral clearance (p=0.01).
RCT 60 hospitalized COVID-19 patients in China showing imporoved recovery and viral clearance with RAY1216, a 3CLpro inhibitor.
Sep 2023, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537023003668, https://c19p.org/wang29

2. Zhan et al., Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial

1,359 patient leritrelvir early treatment RCT: 17% improved recovery (p=0.002) and 16% improved viral clearance (p=0.01).
RCT 1,359 COVID-19 outpatients showing faster recovery with leritrelvir monotherapy (without ritonavir), 251 vs. 271 hours, and improved viral clearance. There were no significant differences in adverse events between groups.
Jan 2024, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537023005369, https://c19p.org/zhan2